Liposomal Bupivacaine Shows Limited Clinical Benefit After Third Molar Extraction

Extended-release anesthetic did not significantly improve postoperative pain, raising questions about its routine use in dental surgery.

Category	Detail
Condition	Postoperative pain management after third molar extraction
Key Mechanisms	Liposomal bupivacaine is an extended-release local anesthetic intended to prolong pain control.
Target Population	Patients undergoing third molar extraction
Care Setting	Dental surgery

Liposomal bupivacaine showed limited clinical benefit in postoperative pain control.
Statistically significant but clinically negligible reduction in opioid consumption (−1.20 MME).
No significant improvement in postoperative pain intensity compared to controls.
Variability across studies in cumulative pain outcomes.
Further research is needed to justify routine use.

Consider standard bupivacaine or placebo over liposomal bupivacaine due to lack of clear superiority.

Caution against routine use of liposomal bupivacaine due to cost and limited efficacy.

Patients undergoing third molar extraction with significant postoperative pain.

Liposomal bupivacaine may reduce opioid prescriptions but does not significantly impact actual opioid consumption or pain outcomes.

Utilize effective nonopioid pain management strategies.
Conduct larger randomized control trials to evaluate liposomal bupivacaine's efficacy.

Clinical Scorecard: Liposomal Bupivacaine Shows Limited Clinical Benefit After Third Molar Extraction